Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People with a confirmed diagnosis of hepatocellular carcinoma (a type of liver cancer)
- People whose liver cancer tumour measures at least 3cm in size
- People who are planned to receive a specialised form of targeted radiation treatment called Stereotactic Body Radiation Therapy (SBRT) for their liver cancer
- People who have previously had a heat-based tumour treatment (radiofrequency ablation) at a different site, or who have had prior surgery
- People whose general health and ability to carry out daily activities meets a standard rating of 0 or 1 on a medical scale (meaning fully active or able to carry out light activity)
- People whose liver is functioning at a level known as Child-Pugh A (a measure of liver health — confirm with trial site)
- People with a life expectancy of more than 12 weeks
- People who have at least one tumour that can be measured using standard imaging criteria
- People whose blood counts, liver function, and kidney function results meet specific minimum levels set by the trial (confirm exact values with trial site)
- People who are able to read, understand, and provide written consent to participate
Who may not be able to join:
- People whose liver cancer is a specific rare subtype, including sarcomatoid HCC, fibrolamellar HCC, or a mixed liver-bile duct cancer
- People who have had another type of cancer within the 5 years before their liver cancer diagnosis
- People who have received a procedure called TACE (a treatment that delivers chemotherapy directly to liver tumours via blood vessels) within the past 3 months
- People who have previously had radiation treatment to the abdomen
- People who have previously received a treatment called yttrium-90 chemoembolization (a type of internal radiation therapy)
- People with a recent history of wounds or ulcers that repeatedly fail to heal, within 2 months of joining the trial
- People who are pregnant or breastfeeding at any point during the study
- People with an active autoimmune disease (where the immune system attacks the body) that has required ongoing medical treatment within the past 2 years
- People with a diagnosed immune system deficiency, including HIV
- People with blood clotting problems or who take blood-thinning medication will not be eligible for the liver biopsy component of the trial (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +852 3505 1042
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To characterize the temporal changes of the biological properties of Circulating tumour DNA, including its relative percentage, fragment size, and end-motif fragment pattern for patients undergoing radiotherapy to Hepatocellular carcinoma.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.